Skip to content
Curis Lifesciences logo

Curis Lifesciences

CURIS NSE
₹181.50 up 1.50 (0.83%)
Market Cap
₹147 Cr

Curis Lifesciences (CURIS) share price was ₹181.50 at the 28 Oct 2026 close; market capitalisation ₹147 Cr; sector Healthcare. In the Mar 2026 quarter, revenue fell 4.8% year on year to ₹32.72 Cr and net profit was ₹2.71 Cr, against ₹4.00 Cr a year earlier (compared with Mar 2025). Promoters held 68.03% of Curis Lifesciences in Sep 2026, unchanged from Mar 2026. Its Tapetide Score is 43/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹181.50 +40.50 +28.72% 1Y

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹147 Cr
EBITDA
₹11.40 Cr
Return on Equity
14.6%
Debt to Equity
0.46
Book Value
₹58.58
EPS (TTM)
—
52W High
₹234.75
52W Low
₹83.60

Price-based figures as of 28 Oct 2026, 15:31 IST · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,763.6034.994,23,147 Cr5.060.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,678.5087.842,56,934 Cr15.330.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,588.3072.031,74,524 Cr9.500.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,195.10108.451,18,604 Cr22.380.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,183.2026.331,18,025 Cr4.350.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,338.8034.671,11,747 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.2032.711,10,289 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Curis Lifesciences (this company)
₹181.50—147 Cr3.100.00%14.60%19.77%9 Cr1 Cr
Median 8 companies₹1,564.4034.991,18,314 Cr4.710.47%14.20%18.45%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

43 Weak
Overall score

Data confidence 98/100

surveillance:ESM1

Category scores

Quality Poor 31
Returns, margins, earnings quality 22% weight
Valuation Weak 43
Cheap vs sector & own history 24% weight
Growth Strong 67
Sales & profit trajectory 9% weight
Financial Health Good 57
Solvency, leverage, coverage 9% weight
Momentum Strong 97
Trend strength, vol-adjusted 12% weight
Ownership Weak 41
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company has a good return on equity (ROE) track record: 3 Years ROE 38.9%

Weaknesses

3
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company might be capitalizing the interest cost
  • Working capital days have increased from 123 days to 232 days

Technical Indicators

Oscillators

Bullish

Bearish
2
Neutral
3
Bullish
4

Overall

Bullish

Bearish
6
Neutral
3
Bullish
10

Moving Averages

Bullish

Bearish
4
Neutral
0
Bullish
6

Growth Rate

Revenue Growth
21.07% higher than 3Y

change over 1 year

Net Income Growth
11.29% lower than 3Y

change over 1 year

Cash Flow Change
-709%

change over 1 year

EBITDA Margin Change
-12.48%

change over 1 year Operating margin 15.71% · Mar 2026

Quarterly Results

Particulars Sep 2024Mar 2025Sep 2025Mar 2026
Sales
15.9
34.36
27.91
32.72
Expenses
12.09
27.43
21.92
27.58
Operating Profit
3.81
6.93
5.99
5.14
OPM %
23.96%
20.17%
21.46%
15.71%
Other Income
-0.02
0.05
0
0.27
Interest
0.5
0.61
0.43
0.71
Depreciation
0.34
0.34
0.34
0.35
PBT
2.95
6.03
5.22
4.35
Tax %
25.42%
33.67%
19.35%
37.7%
Net Profit
2.2
4
4.21
2.71
EPS (₹)
4
6.74
7.09
3.35
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
23.7
35.21
35.13
50.26
60.63
Expenses
20.12
31.95
26.74
39.51
49.5
Operating Profit
3.58
3.26
8.39
10.75
11.13
OPM %
15.11%
9.26%
23.88%
21.39%
18.36%
Other Income
0.02
0.34
0.31
0.02
0.27
Interest
1.62
1.33
0.85
1.11
1.14
Depreciation
0.75
0.73
0.68
0.67
0.7
PBT
1.23
1.54
7.17
8.99
9.56
Tax %
59.35%
20.13%
32.22%
30.92%
27.62%
Net Profit
0.49
1.23
4.87
6.21
6.92
EPS (₹)
0.89
2.24
8.85
10.46
8.56
Div. Payout %
0%
0%
0%
0%
0%
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.5
0.5
0.5
5.93
8.08
Reserves
-1.4
-0.18
5.37
10.58
39.27
Borrowings
17.62
16.19
17.09
15.61
21.59
Other Liabilities
10.68
13.16
10.91
10.48
12.58
Total Liabilities
27.4
29.67
33.87
42.6
81.52
Fixed Assets
12.33
12.2
11.59
10.99
10.78
CWIP
0
0
0
0.02
1.33
Investments
0.01
0.01
0.01
0.01
0.01
Other Assets
15.06
17.46
22.27
31.58
69.4
Total Assets
27.4
29.67
33.87
42.6
81.52
Figures in ₹ Crores

Cash Flow

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
4.95
3.35
0.28
-2.03
-16.42
Investing
-0.37
-0.55
-0.06
-0.02
-1.59
Financing
-4.58
-2.76
0.05
1.94
20.87
Net Cash Flow
-0.01
0.04
0.27
-0.11
2.86
Free Cash Flow
4.56
2.77
0.21
-2.06
-18.24
CFO/EBITDA
138
103
3
-5
-127
Figures in ₹ Crores

Ratios

Particulars Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
96.1
98.17
105
55.05
67.55
Inventory Days
208
115
273
347
694
Days Payable
360
263
210
113
166
Cash Conversion Cycle
-55.01
-49.58
168
289
595
Working Capital Days
-16.02
-20.84
36.26
99.27
232
ROCE %
—
17.21%
40.64%
36.64%
21.2%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Curis Lifesciences insights

62 extracted metrics + investor summaries across FY22–FY26.

Shareholding Pattern

FIIs1.05%Promot.68.03%DIIs4.63%Others10.51%Public15.78%As ofSep 2026

Documents

Frequently Asked Questions about Curis Lifesciences

What does Curis Lifesciences Ltd do?
Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]
Where is Curis Lifesciences Ltd (CURIS) listed?
Curis Lifesciences Ltd trades as CURIS on the NSE.
Which sector does Curis Lifesciences Ltd belong to?
Curis Lifesciences Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Curis Lifesciences Ltd?
Curis Lifesciences Ltd has a market capitalisation of ₹146.73 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the 52-week high and low of Curis Lifesciences Ltd?
Over the last 52 weeks Curis Lifesciences Ltd has traded between ₹83.6 and ₹234.75 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Curis Lifesciences Ltd?
Curis Lifesciences Ltd reported a return on equity of 14.60%. Its debt-to-equity ratio is 0.46.

Company Information

Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company that specializes in developing, manufacturing, and distributing a diverse range of products.[1]

Website curisls.com
Listed 2025-11-14
Face Value ₹ 10
Shares Outstanding 80,84,434

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/CURIS.md for Curis Lifesciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month